In a groundbreaking study, Celergen is shown to offer relief from chronic inflammation in a way not previously thought possible.

What is Inflammation?

Inflammation is the body’s natural response to injury and infection in an effort to heal and repair itself, as well act as a self-defense from foreign invaders. However, if constant or if occurring where it’s not needed, inflammation is considered chronic and unhealthy. Judged by a small rise in immune system markers (neuro-cytokines) found in blood and tissue, chronic inflammation can contribute to the development of diseases and conditions such as autoimmune disorders, arthritis, diabetes and cancer among others, as stated in the Johns Hopkins Health Review. Furthermore, high levels of inflammation weaken and compromise your immune system, leaving you vulnerable to contagious diseases and viral infections.

“Celergen seems to instinctively know where you have the most inflammation or degeneration in your body. It's a smart treatment - working according to the specific needs of the individual. ”

Dr. Alex Alonso, Life Wellness Institute

Inflammatory Markers

In this specific study, the inflammatory markers Substance P (SP) and Tumor Necrosis Factor (TNFa) were found in participants suffering from multiple conditions associated with chronic inflammation and compared to that of a healthy control group without symptoms, and whose inflammatory blood markers were deemed normal.


    Prior to starting Celergen, extensive blood tests were performed on the participants suffering from inflammatory related conditions looking for any common abnormalities as compared to the healthy members of a control group.

    Substance P and TNFa

    In this particular study, participants suffering from inflammatory-related conditions all shared abnormally high levels of the pro-inflammatory markers of Substance P (SP) and Tumor Necrosis Factor (TNFa) as compared to their counterparts in the control group.

    Celergen Effect on SP

    Substance P (SP) levels at the beginning of the study for inflammatory sufferers were significantly elevated (0.68 ± 0.31 ng/mL) as compared to healthy controls (0.41 ± 0.31 ng/mL). Remarkably, at the end of the study, the inflammatory participant levels of SP (0.27 ± 0.09 ng/mL) were 35% lower than the healthy controls.

    Celergen Effect on TNFa

    TNFa levels were also significantly increased (3.34 ± 3.12 pg/mL) in participants with inflammatory related conditions at the beginning of the study as compared to healthy controls (0.55 ± 0.41 pg/mL). At the end of the study, inflammatory participant levels were significantly reduced (1.64 ± 1.24 pg/mL) – well below unhealthy levels.

“Upon assessing the elevated inflammatory markers of a patient of mine, I recommended Celergen. The results were amazing, and I believe that the use of Celergen continues to lower his disease risk.”

Dr. Cara Van Wormer-Hartman, Therapeutic Health Associates

Inflammatory Symptoms

As stated above, chronic inflammation can lead to various conditions and diseases. Initially, chronic inflammation may not always be apparent, but the participants of this study shared symptoms characterized by chronic widespread musculoskeletal pain, sleep disturbances, stiffness, fatigue and cognitive dysfunction.


    Participants between the ages of 18 and 80 were chosen after reportedly suffering from the above symptoms for a period longer than six months.


    During the first month of the 3 month treatment, 100% of participants experienced at least an 80% reduction of all inflammatory related symptoms.

"This is the first time to our knowledge that any molecule can reduce blood levels of Substance P in any disease..."

Theoharis C. Theoharides, Dept of Integrative Physiology & Pathobiology, Tufts University

Understanding Substance P & TNFa

The study participants above were chosen due to the symptoms and conditions that they had experienced for an extended period of time. What was surprisingly common among all participants were the high levels of neuroimmune mediators, better known as inflammatory markers or neuro-cytokines, in their blood levels – specifically, Substance P (SP) and Tumor Necrosis Factor (TNFa). Both of these markers are known to have proinflammatory actions. However, what was not conclusive prior to this study was each marker’s relation to the other. Substance P, the lessor known of the two above markers, appears to be secreted based on a number of factors including physiological and/or psychological stress. An increase in Substance P levels are known to stimulate immune cells – particularly mast cells. Known to be involved not only in allergic conditions, mast cells are also related to inflammatory diseases. Interestingly, in this study mast cells were significantly increased in the papillary dermis of study participants who also often experienced chronic urticaria – an inflammatory skin condition. Furthermore, located perivascularly adjacent to neurons both in the skin and in the brain, activated mast cells secrete numerous nuerosensitizing and pro-inflammatory mediators that contribute to inflammatory-related symptoms, including pain. Among the pro-inflammatory mediators secreted by mast cells is Tumor Necrosis Factor (TNFa). In fact, mast cells are the only immune cells to store TNFa and will secrete it rapidly when stimulated, such as with the increase in Substance P levels as explained above. Chronic high levels of TNFa are tied to several inflammatory diseases including Rheumatoid arthritis, Chron’s disease, Ulcerative colitis, Ankylosing Spondylitis and many others including cancer. According to lead researcher, Dr. Theoharis C. Theoharides of Tufts University, Celergen is the “only known molecule that can reduce blood levels of Substance P in any disease.” Thereby reducing the level of mast cells and the accompanying over secretion of TNFa.


There is a direct correlation between inflammatory markers Substance P, TNFa and the symptoms experienced above. Therefore, it is of no surprise that Celergen - if taken daily - will not only reduce the abnormal proinflammatory markers of Substance P and TNFa on a significant level, but their symptoms as well.